Registry on Hypomethylating Agents in Myeloid Neoplasms, Including Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) and Acute Myeloid Leukemia (AML)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 27 Mar 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Azacitidine (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Myeloid leukaemia
Focus Therapeutic Use

22 Mar 2024 Status changed from active, no longer recruiting to completed.
14 Dec 2021 Results (data cut off 13 Dec 20) presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
14 Dec 2021 Primary endpoint has been met (Overall survival) asper Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com